The DOI matches its Crossref record.
The Molecular Target of Rapamycin (mTOR) as a Therapeutic Target Against Cancer
Open accessAbstract
The molecular target of rapamycin (mTOR), which is a member of the phosphoinositide 3-kinase related kinase (PIKK) family and a central modulator of cell growth, is a prime strategic target for anti-cancer therapeutic development. mTOR plays a critical role in transducing proliferative signals mediated through the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt) signaling pathway, principally by activating downstream protein kinases that are required for both ribosomal biosynthesis and translation of key mRNAs of proteins required for G(1) to S phase traverse. By targeting mTOR, the immunsuppressant and antiproliferative agent rapamycin (RAP) inhibits signals required for cell cycle progression, cell growth, and proliferation. RAP, a complex macrolide and highly potent fungicide, immunosuppressant, and anti-cancer agent, is a highly specific inhibitor of mTOR. In essence, RAP gains function by binding to the immunophilin FK506 binding protein 12 (FKBP12) and the resultant complex inhibits the activity of mTOR. Since mTOR activates both the 40S ribosomal protein S6 kinase ((p)70(s6k)) and the eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), RAP blocks activation of these downstream signaling elements, which results in cell cycle arrest in the G1 arrest. RAP also prevents cyclin-dependent kinase (cdk) activation, inhibits retinoblastoma protein ((p)Rb) phosphorylation, and accelerates the turnover of cyclin D1 that leads to a deficienciy of active cdk4/cyclin D1 complexes, all of which potentially contribute to the prominent inhibitory effects of RAP at the G(1)/S phase transition. Both RAP and several RAP analogs with more favorable pharmaceutical properties have demonstrated prominent growth inhibitory effects against a broad range of human cancers in both preclinical and early clinical evaluations. This review will summarize the principal mechanisms of action of RAP and RAP derivatives and their potential utility of these agents as anti-cancer therapeutics. The preliminary results of early clinical evaluations with RAP analogs and the unique developmental challenges that lie ahead will also be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Rapamycin, But Not Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice
Miller, R. A., Harrison, D. E., Astle, C. M., Baur, J. A., Boyd, A. R., de Cabo, R., Fernandez, E., Flurkey, K., Javors, M. A., Nelson, J. F., et al. (2011) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glq178 · Cited by 896
Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime?
Fuchs, B. C., & Bode, B. P. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.04.005 · Cited by 680
Taylor, A. L., Watson, C. J. E., & Bradley, J. A. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.03.012 · Cited by 445
Zhou, X., Tan, M., Stone Hawthorne, V., Klos, K. S., Lan, K.-H., Yang, Y., Yang, W., Smith, T. L., Shi, D., & Yu, D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0112 · Cited by 312
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
Rudelius, M., Pittaluga, S., Nishizuka, S., Pham, T. H.-T., Fend, F., Jaffe, E. S., Quintanilla-Martinez, L., & Raffeld, M. (2006) · Blood · doi:10.1182/blood-2006-04-015586 · Cited by 277
The PI3K-Akt-mTOR pathway regulates Aβ oligomer induced neuronal cell cycle events
Bhaskar, K., Miller, M., Chludzinski, A., Herrup, K., Zagorski, M., & Lamb, B. T. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-14 · Cited by 177
mTOR function in skeletal muscle hypertrophy: Increased ribosomal RNA via cell cycle regulators
Nader, G. A., McLoughlin, T. J., & Esser, K. A. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00165.2005 · Cited by 166
Metadata
- Authors
- Mita, M. M., Mita, A., & Rowinsky, E. K.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2003-03
- Volume
- 2
- Issue
- sup1
- Pages
- 168-176
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2050026229
- Cited by
- 170
- References
- 0
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.